US Reclassifies Marijuana to Lower Danger Category

The Trump administration has reclassified marijuana from Schedule I to Schedule III controlled substances, placing it in the same category as medications like Tylenol with codeine. The move is expected to ease restrictions on medical research and potentially accelerate legalization efforts across American states.

In a significant shift in drug policy, the Trump administration announced the reclassification of marijuana to Schedule III status under federal law. This decision moves the substance away from Schedule I, which previously classified it alongside heroin and LSD as having no accepted medical use and high abuse potential. The new classification aligns marijuana with prescription medications that contain codeine, such as Tylenol with codeine, indicating federal recognition of potential medical applications.

The reclassification addresses a long-standing debate over marijuana's medical and recreational value. Previously, researchers faced substantial federal barriers when attempting to study cannabis for therapeutic purposes, as Schedule I drugs carry the most severe restrictions on scientific investigation. By moving to Schedule III, the substance will fall under different regulatory constraints that could facilitate clinical trials and pharmaceutical research into cannabinoid-based treatments.

This administrative action reflects shifting attitudes toward cannabis policy in the United States. Numerous American states have already legalized marijuana for medical or recreational purposes, creating a disconnect between state and federal law. The reclassification may accelerate these legalization trends and provide states with greater flexibility in establishing their own cannabis regulations without direct federal interference.

The implications extend beyond research and state policy to the broader cannabis industry. Current restrictions have limited banking access and business deductions for cannabis companies operating in states where it is legal. A lower federal classification could potentially open financial services and tax relief opportunities for the industry, though significant restrictions would likely remain.

Legal experts note that while the reclassification represents a major policy shift, it does not constitute full legalization at the federal level. The substance remains a controlled drug, meaning possession and distribution without proper licensing remain illegal under federal law. However, the move signals the Trump administration's willingness to reconsider long-standing drug policies based on evolving scientific understanding.